PNT Stock Overview
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer.
Notes are coming soon
POINT Biopharma Global Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.22|
|52 Week High||US$10.98|
|52 Week Low||US$5.23|
|1 Month Change||6.96%|
|3 Month Change||-26.18%|
|1 Year Change||14.60%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-39.93%|
Recent News & Updates
|PNT||US Biotechs||US Market|
Return vs Industry: PNT exceeded the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: PNT exceeded the US Market which returned -8.5% over the past year.
|PNT Average Weekly Movement||12.8%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: PNT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PNT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies.
POINT Biopharma Global Inc. Fundamentals Summary
|PNT fundamental statistics|
Is PNT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PNT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.75|
|Net Profit Margin||0.00%|
How did PNT perform over the long term?See historical performance and comparison